EA200101268A1 - Способ тиазола, фармацевтические препараты для ингибирования протеинкиназ и способы их применения - Google Patents
Способ тиазола, фармацевтические препараты для ингибирования протеинкиназ и способы их примененияInfo
- Publication number
- EA200101268A1 EA200101268A1 EA200101268A EA200101268A EA200101268A1 EA 200101268 A1 EA200101268 A1 EA 200101268A1 EA 200101268 A EA200101268 A EA 200101268A EA 200101268 A EA200101268 A EA 200101268A EA 200101268 A1 EA200101268 A1 EA 200101268A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- modulate
- cell proliferation
- pharmaceutical preparations
- preparations containing
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 102000001253 Protein Kinase Human genes 0.000 title abstract 2
- 108060006633 protein kinase Proteins 0.000 title abstract 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000004663 cell proliferation Effects 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- WKXCZMFWXZRMEZ-UHFFFAOYSA-N 1,3-thiazole-2,4-diamine Chemical class NC1=CSC(N)=N1 WKXCZMFWXZRMEZ-UHFFFAOYSA-N 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 201000003142 neovascular glaucoma Diseases 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13781099P | 1999-06-04 | 1999-06-04 | |
| PCT/US2000/015188 WO2000075120A1 (en) | 1999-06-04 | 2000-06-02 | Diaminothiazoles and their use for inhibiting protein kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200101268A1 true EA200101268A1 (ru) | 2002-06-27 |
Family
ID=22479135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200101268A EA200101268A1 (ru) | 1999-06-04 | 2000-06-02 | Способ тиазола, фармацевтические препараты для ингибирования протеинкиназ и способы их применения |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US6620828B2 (https=) |
| EP (1) | EP1181283B1 (https=) |
| JP (1) | JP2003501420A (https=) |
| KR (1) | KR20020015333A (https=) |
| CN (1) | CN1359380A (https=) |
| AP (1) | AP2001002341A0 (https=) |
| AT (1) | ATE288424T1 (https=) |
| AU (1) | AU778071B2 (https=) |
| BG (1) | BG106276A (https=) |
| BR (1) | BR0011585A (https=) |
| CA (1) | CA2371158A1 (https=) |
| CZ (1) | CZ20014213A3 (https=) |
| DE (1) | DE60017894T2 (https=) |
| EA (1) | EA200101268A1 (https=) |
| EE (1) | EE200100659A (https=) |
| ES (1) | ES2234628T3 (https=) |
| HR (1) | HRP20020008A2 (https=) |
| HU (1) | HUP0202897A3 (https=) |
| IL (1) | IL146094A0 (https=) |
| IS (1) | IS6183A (https=) |
| MA (1) | MA25530A1 (https=) |
| MX (1) | MXPA01012483A (https=) |
| NO (1) | NO20015045L (https=) |
| NZ (1) | NZ514881A (https=) |
| OA (1) | OA11959A (https=) |
| PE (1) | PE20010211A1 (https=) |
| PL (1) | PL352714A1 (https=) |
| SK (1) | SK17302001A3 (https=) |
| SV (1) | SV2002000096A (https=) |
| UA (1) | UA71971C2 (https=) |
| UY (1) | UY26190A1 (https=) |
| WO (1) | WO2000075120A1 (https=) |
| YU (1) | YU85601A (https=) |
| ZA (1) | ZA200108291B (https=) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020150921A1 (en) * | 1996-02-09 | 2002-10-17 | Francis Barany | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
| PL342447A1 (en) * | 1997-10-27 | 2001-06-04 | Agouron Pharma | Substituted 4-amino thiazol-2-yl compounds as inhibitors of cyclin-dependent kinases |
| US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US20040226056A1 (en) * | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
| EP1169038B9 (en) | 1999-04-15 | 2013-07-10 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| WO2002050071A1 (en) | 2000-12-21 | 2002-06-27 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of tec family tyrosine kinases |
| US6756374B2 (en) | 2001-01-22 | 2004-06-29 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
| UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| JP2005504014A (ja) * | 2001-06-08 | 2005-02-10 | サイトビア インコーポレイテッド | カスパーゼの活性化因子およびアポトーシスの誘導因子としての置換された３−アリール−５−アリール−［１，２，４］−オキサジアゾール類および類似体、並びにその使用法 |
| EP1467981A1 (en) * | 2002-01-25 | 2004-10-20 | Kylix Pharmaceuticals B.V. | 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
| US6818663B2 (en) * | 2002-05-17 | 2004-11-16 | Hoffmann-La Roches | Diaminothiazoles |
| MXPA05001277A (es) * | 2002-08-02 | 2005-10-06 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit. |
| US8450302B2 (en) | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| AU2003278600A1 (en) * | 2002-11-01 | 2004-05-25 | Takeda Pharmaceutical Company Limited | Agent for preventing or treating neuropathy |
| MXPA05008878A (es) * | 2003-02-21 | 2005-10-05 | Pfizer | Derivados de aminotiazol sustituidos con cicloalquilo que contiene n y composiciones farmaceuticas para inhibir la proliferacion celular, y metodos para su uso. |
| US7078419B2 (en) | 2003-03-10 | 2006-07-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cytokine inhibitors |
| HUE047569T2 (hu) | 2003-04-11 | 2020-04-28 | Ptc Therapeutics Inc | 1,2,4-oxadiazol-benzoesav vegyület és nonszensz szupresszióra történõ alkalmazása |
| WO2004092217A1 (en) * | 2003-04-17 | 2004-10-28 | Pfizer Inc. | Crystal structure of vegfrkd: ligand complexes and methods of use thereof |
| WO2005007091A2 (en) * | 2003-07-07 | 2005-01-27 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
| EP1663204B1 (en) * | 2003-08-29 | 2014-05-07 | Exelixis, Inc. | C-kit modulators and methods of use |
| EP2060270A3 (en) * | 2003-10-16 | 2009-12-09 | Imclone LLC | Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
| AU2005205201B2 (en) | 2004-01-12 | 2011-05-12 | Merck Serono Sa | Thiazole derivatives and use thereof |
| JPWO2005108370A1 (ja) * | 2004-04-16 | 2008-03-21 | 味の素株式会社 | ベンゼン化合物 |
| US7211576B2 (en) | 2004-04-20 | 2007-05-01 | Hoffmann-La Roche Inc. | Diaminothiazoles |
| AU2005271843A1 (en) * | 2004-07-12 | 2006-02-16 | Merck Sharp & Dohme Corp. | Histone deacetylase inhibitors |
| WO2006125807A1 (en) | 2005-05-24 | 2006-11-30 | Laboratoires Serono S.A. | Thiazole derivatives and use thereof |
| CN101248054B (zh) * | 2005-05-24 | 2012-05-09 | 默克雪兰诺有限公司 | 噻唑衍生物及其应用 |
| EP1945632B1 (en) | 2005-11-08 | 2013-09-18 | Vertex Pharmaceuticals Incorporated | Heterocyclic modulators of atp-binding cassette transporters |
| AU2006336504C9 (en) * | 2005-12-28 | 2015-05-14 | Vertex Pharmaceuticals Incorporated | 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis |
| AU2012244242B2 (en) * | 2005-12-28 | 2015-05-21 | Vertex Pharmaceuticals Incorporated | 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis |
| WO2007084391A2 (en) * | 2006-01-18 | 2007-07-26 | Amgen Inc. | Thiazole compounds as protein kinase b ( pkb) inhibitors |
| CN101484433A (zh) * | 2006-02-15 | 2009-07-15 | 艾博特公司 | 新的乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用 |
| JP2009526868A (ja) * | 2006-02-15 | 2009-07-23 | アボット・ラボラトリーズ | 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用 |
| RU2462246C2 (ru) | 2006-03-30 | 2012-09-27 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы получения функционального белка из днк, имеющей нонсенс-мутацию, и лечения нарушений, ассоциированных с ней |
| CN101501023A (zh) * | 2006-07-07 | 2009-08-05 | 贝林格尔.英格海姆国际有限公司 | 苯基取代的杂芳基衍生物及其作为抗肿瘤剂的用途 |
| WO2008080134A2 (en) | 2006-12-22 | 2008-07-03 | Rigel Pharmaceuticals, Inc. | 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors |
| US8969386B2 (en) | 2007-05-09 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| CA2692379A1 (en) * | 2007-07-02 | 2009-01-08 | Boehringer Ingelheim International Gmbh | Antiproliferative compounds based on 5-membered heterocycles |
| CL2008001943A1 (es) | 2007-07-02 | 2009-09-11 | Boehringer Ingelheim Int | Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes. |
| US7919504B2 (en) * | 2007-07-17 | 2011-04-05 | Amgen Inc. | Thiadiazole modulators of PKB |
| EP2173728A2 (en) | 2007-07-17 | 2010-04-14 | Amgen Inc. | Heterocyclic modulators of pkb |
| EP2639224B1 (en) | 2007-12-07 | 2016-08-24 | Vertex Pharmaceuticals Incorporated | Process for producing cycloalkylcarboxiamido-pyridine benzoic acids |
| SI2225230T1 (sl) | 2007-12-07 | 2017-03-31 | Vertex Pharmaceuticals Incorporated | Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline |
| WO2009076140A1 (en) * | 2007-12-13 | 2009-06-18 | Smithkline Beecham Corporation | Thiazole and oxazole kinase inhibitors |
| NZ720282A (en) | 2008-02-28 | 2017-12-22 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| US8778929B2 (en) | 2008-09-29 | 2014-07-15 | Boehringer Ingelheim International Gmbh | Substituted heteroaryl inhibitors of B-RAF |
| PL2387395T3 (pl) | 2009-01-16 | 2015-03-31 | Rigel Pharmaceuticals Inc | Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowym |
| EP2492269A4 (en) * | 2009-10-19 | 2013-08-07 | Taisho Pharmaceutical Co Ltd | aminothiazole |
| WO2011117382A1 (en) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | Pyridyltriazoles |
| WO2011117381A1 (en) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | B-raf kinase inhibitors |
| HRP20211752T1 (hr) | 2010-04-07 | 2022-02-18 | Vertex Pharmaceuticals Incorporated | Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena |
| US8710055B2 (en) | 2010-12-21 | 2014-04-29 | Boehringer Ingelheim International Gmbh | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| WO2013112804A1 (en) | 2012-01-25 | 2013-08-01 | Vertex Pharmaceuticals Incorporated | Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| TW201350479A (zh) | 2012-04-26 | 2013-12-16 | Ono Pharmaceutical Co | Ｔｒｋ阻害化合物 |
| AU2014219855B2 (en) | 2013-02-19 | 2017-09-28 | Ono Pharmaceutical Co., Ltd. | Trk-inhibiting compound |
| GB201309333D0 (en) | 2013-05-23 | 2013-07-10 | Agency Science Tech & Res | Purine diones as WNT pathway modulators |
| JP6963896B2 (ja) | 2013-11-12 | 2021-11-10 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法 |
| KR102497273B1 (ko) | 2014-03-06 | 2023-02-07 | 피티씨 테라퓨틱스, 인크. | 1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염 |
| PT3221692T (pt) | 2014-11-18 | 2021-09-10 | Vertex Pharma | Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência |
| JP2018531975A (ja) | 2015-10-30 | 2018-11-01 | ピーティーシー セラピューティクス，インコーポレーテッド | てんかんの治療方法 |
| WO2018052967A1 (en) * | 2016-09-13 | 2018-03-22 | Arbutus Biopharma, Inc. | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same |
| CN111233786B (zh) * | 2020-02-04 | 2021-11-26 | 中国人民解放军军事科学院军事医学研究院 | 含五元杂环的苯磺酰胺类化合物及其制备方法和用途 |
| CN121443601A (zh) * | 2023-07-03 | 2026-01-30 | 英矽智能科技知识产权有限公司 | 作为cdk2/4/6抑制剂的取代的噻唑化合物及其使用方法 |
| CN116874442B (zh) * | 2023-07-27 | 2025-10-24 | 武汉呈瑞生物医药科技有限公司 | 一种有机化合物及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE273062C (de) | 1912-04-19 | 1914-04-20 | Deylen Sohn Firma | Vorrichtung zum Schränken von Plattenzündspänen |
| AU558132B2 (en) | 1981-05-27 | 1987-01-22 | Labatt Brewing Co. Ltd. | Malt sterilisation with hydrogen peroxide |
| EP0218728A1 (en) | 1985-04-03 | 1987-04-22 | Yamanouchi Pharmaceutical Co. Ltd. | Phenylene derivatives |
| SG64322A1 (en) * | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| JPH07505155A (ja) | 1992-03-24 | 1995-06-08 | メルク シヤープ エンド ドーム リミテツド | コレシストキニン及び／又はガストリン拮抗活性を有する３−ウレイド置換ベンゾジアゼピン−２−オン及び治療におけるその使用 |
| US5631156A (en) | 1994-06-21 | 1997-05-20 | The University Of Michigan | DNA encoding and 18 KD CDK6 inhibiting protein |
| WO1996014843A2 (en) | 1994-11-10 | 1996-05-23 | Cor Therapeutics, Inc. | Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases |
| DK0808312T3 (da) | 1995-02-02 | 2001-02-12 | Smithkline Beecham Plc | Indolderivater som 5-HT-receptorantagonist |
| US5710173A (en) | 1995-06-07 | 1998-01-20 | Sugen, Inc. | Thienyl compounds for inhibition of cell proliferative disorders |
| AU6526896A (en) | 1995-07-22 | 1997-02-18 | Rhone-Poulenc Rorer Limited | Substituted aromatic compounds and their pharmaceutical use |
| US5705499A (en) | 1995-10-06 | 1998-01-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | 8-arylalkyl- and 8-arylheteroalkyl-5,11-dihydro-6H-dipyrido 3,2-B:2',3'-e! 1!diazepines and their use in the treatment of HIV-1 infection |
| US5733920A (en) | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
| US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| AU2103097A (en) | 1996-03-15 | 1997-10-10 | Zeneca Limited | Cinnoline derivatives and use as medicine |
| EP0816357B1 (en) | 1996-06-27 | 2002-01-09 | Pfizer Inc. | Substituted indazole derivatives |
| EA002113B1 (ru) | 1996-09-04 | 2001-12-24 | Пфайзер Инк. | Производные индазола и их использование в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продуцирования фактора некроза опухоли (фно) |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| PL342447A1 (en) * | 1997-10-27 | 2001-06-04 | Agouron Pharma | Substituted 4-amino thiazol-2-yl compounds as inhibitors of cyclin-dependent kinases |
| IL135714A0 (en) | 1997-11-04 | 2001-05-20 | Pfizer Prod Inc | Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors |
| IL135900A0 (en) | 1997-11-04 | 2001-05-20 | Pfizer Prod Inc | Indazole bioisostere replacement of catechol in therapeuticaly active compounds |
| US6040321A (en) * | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| EP1087951B9 (en) * | 1998-06-18 | 2006-09-13 | Bristol-Myers Squibb Company | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases |
| ATE255575T1 (de) | 1998-09-29 | 2003-12-15 | Wyeth Corp | Substituierte 3-cyanochinoline als protein tyrosine kinase inhibitoren |
-
2000
- 2000-02-06 UA UA2001129215A patent/UA71971C2/uk unknown
- 2000-06-02 WO PCT/US2000/015188 patent/WO2000075120A1/en not_active Ceased
- 2000-06-02 EE EEP200100659A patent/EE200100659A/xx unknown
- 2000-06-02 CZ CZ20014213A patent/CZ20014213A3/cs unknown
- 2000-06-02 UY UY26190A patent/UY26190A1/es not_active Application Discontinuation
- 2000-06-02 CN CN00808440A patent/CN1359380A/zh active Pending
- 2000-06-02 DE DE60017894T patent/DE60017894T2/de not_active Expired - Fee Related
- 2000-06-02 OA OA1200100321A patent/OA11959A/en unknown
- 2000-06-02 BR BR0011585-1A patent/BR0011585A/pt not_active IP Right Cessation
- 2000-06-02 EA EA200101268A patent/EA200101268A1/ru unknown
- 2000-06-02 IL IL14609400A patent/IL146094A0/xx unknown
- 2000-06-02 AP APAP/P/2001/002341A patent/AP2001002341A0/en unknown
- 2000-06-02 EP EP00942660A patent/EP1181283B1/en not_active Expired - Lifetime
- 2000-06-02 HR HR20020008A patent/HRP20020008A2/hr not_active Application Discontinuation
- 2000-06-02 SV SV2000000096A patent/SV2002000096A/es unknown
- 2000-06-02 MX MXPA01012483A patent/MXPA01012483A/es not_active Application Discontinuation
- 2000-06-02 PL PL00352714A patent/PL352714A1/xx not_active Application Discontinuation
- 2000-06-02 HU HU0202897A patent/HUP0202897A3/hu unknown
- 2000-06-02 JP JP2001501601A patent/JP2003501420A/ja not_active Abandoned
- 2000-06-02 KR KR1020017015384A patent/KR20020015333A/ko not_active Withdrawn
- 2000-06-02 CA CA002371158A patent/CA2371158A1/en not_active Abandoned
- 2000-06-02 NZ NZ514881A patent/NZ514881A/en unknown
- 2000-06-02 YU YU85601A patent/YU85601A/sh unknown
- 2000-06-02 ES ES00942660T patent/ES2234628T3/es not_active Expired - Lifetime
- 2000-06-02 AU AU57254/00A patent/AU778071B2/en not_active Ceased
- 2000-06-02 PE PE2000000553A patent/PE20010211A1/es not_active Application Discontinuation
- 2000-06-02 AT AT00942660T patent/ATE288424T1/de not_active IP Right Cessation
- 2000-06-02 SK SK1730-2001A patent/SK17302001A3/sk unknown
-
2001
- 2001-02-15 US US09/783,584 patent/US6620828B2/en not_active Expired - Fee Related
- 2001-10-09 ZA ZA200108291A patent/ZA200108291B/xx unknown
- 2001-10-17 NO NO20015045A patent/NO20015045L/no not_active Application Discontinuation
- 2001-11-29 IS IS6183A patent/IS6183A/is unknown
-
2002
- 2002-01-02 MA MA26465A patent/MA25530A1/fr unknown
- 2002-01-03 BG BG106276A patent/BG106276A/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200101268A1 (ru) | Способ тиазола, фармацевтические препараты для ингибирования протеинкиназ и способы их применения | |
| EA200200120A1 (ru) | Соединения индазола, фармацевтические препараты для ингибирования протеинкиназ и способы их применения | |
| TWI262914B (en) | Compounds and pharmaceutical compositions for inhibiting protein kinases | |
| EA200200768A1 (ru) | Соединения индазола, фармацевтические композиции и методы модуляции или ингибирования клеточной пролиферации | |
| EA199900021A1 (ru) | Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы | |
| EA200500811A1 (ru) | 2-(1h-индазол-6-иламино)бензамидные соединения как ингибиторы протеинкиназ, полезные для лечения офтальмологических заболеваний | |
| MXPA06001193A (es) | Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibir la proliferacion celular. | |
| Dumler et al. | The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells | |
| Grothe | The evolution of temporal processing in the medial superior olive, an auditory brainstem structure | |
| BR0108025A (pt) | Compostos de amida, sal farmaceuticamente aceitável de um metabólito farmaceuticamente ativo do composto, composição farmacêutica para modular ou inibir a atividade de um receptor de proteìna cinase, método de tratamento de uma condição doentia de mamìferos mediada pela atividade de proteìna cinase e método para modular ou inibir a atividade de um receptor de proteìna cinase | |
| ATE265456T1 (de) | 2-amino-6-anilino-purine und deren verwendung als arzneimittel | |
| EA200200473A1 (ru) | Ингибиторы тирозинкиназы | |
| EA200001176A1 (ru) | Гетероциклические ингибиторы p38 | |
| EP0954334A4 (en) | Use of macrophage migration inhibitory factor antagonists for cancer therapy | |
| FR2736915B1 (fr) | Variants de la proteine p53 et utilisations therapeutiques | |
| Caccia et al. | Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line | |
| MY117667A (en) | Pyrazole-thiazole compounds, pharmaceutical compositions containing them | |
| HUP9900011A2 (hu) | A GAX protein alkalmazása rák kezelésére | |
| DE69814691D1 (de) | Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten | |
| DE69832374D1 (de) | Cyclin abhängige kinase(cdk)4 hemmer und deren verwendung zur behandlung von krebs | |
| TH75180B (th) | สารประกอบอินดาโซลและองค์ประกอบทางเภสัชภัณฑ์ในการยับยั้งโปรตีนไคเนสและวิธีใช้ประโยชน์ | |
| DOP2003000788A (es) | Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas, y procedimientos para su uso |